An open multiple dose study of Optrex Eye Lotion in eye irritation due to hayfever.
Twenty-four patients consulting their general practitioner with eye irritation due to hayfever entered a seven-day open, multiple dose study of a newly formulated Optrex Eye Lotion. Patients self-administered Optrex by irrigation into their left eye three times daily for seven days, with an option to use the same preparation in their right eye if they thought this to be of benefit. Assessment was by means of daily diary cards completed by the patient each evening for the seven-day period. Following the first instillation, the treated eye felt significantly better at 20 seconds and at four minutes when compared with the untreated eye. Differences between the eyes for degree of redness, comfort and clearness of vision were not significant, but 15 patients (63 per cent) optionally used Optrex in their right eye. Seventeen patients (71 per cent) reported that they derived overall benefit from the use of Optrex Eye Lotion during the study period. Two patients reported side effects during the study but, in each case, the investigator did not consider the event to be therapy related. One patient withdrew on Day 7 of the trial due to worsening of their allergic conjunctivitis. It can be concluded that some subjective benefit was gained by the majority of patients in that a considerable number of them chose to treat both eyes for the duration of the study.
Clark
M J
MJ
Chapman
N D
ND
Noyelle
R M
RM
Lancaster
L
L
D000287:Administration, Topical; D000328:Adult; D000481:Allantoin / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001888:Boric Acids / Q000008:administration & dosage*; D002724:Chlorobutanol / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D012459:Salicylates / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D001888:Boric Acids; D004338:Drug Combinations; D009883:Ophthalmic Solutions; C063568:Optrex Eye Lotion; D012459:Salicylates; D000481:Allantoin; D002724:Chlorobutanol